Friday, May 01, 2020 7:38:13 AM
Phase 2 study $2.20
D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.
Recent AKTX News
- Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors • GlobeNewswire Inc. • 04/21/2026 01:00:00 PM
- Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing • GlobeNewswire Inc. • 04/20/2026 12:35:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/16/2026 04:15:07 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/10/2026 08:15:02 PM
- Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC • GlobeNewswire Inc. • 04/09/2026 12:50:00 PM
- Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing • GlobeNewswire Inc. • 04/06/2026 12:45:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:39:37 PM
- Akari Therapeutics to present ADC research at AACR Annual Meeting 2026 • IH Market News • 03/18/2026 03:02:39 PM
- Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 • GlobeNewswire Inc. • 03/18/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 09:07:26 PM
- Akari Therapeutics Announces ADS Ratio Change • GlobeNewswire Inc. • 03/17/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:00:03 PM
- Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala • GlobeNewswire Inc. • 03/13/2026 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 10:00:26 PM
- Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board • GlobeNewswire Inc. • 02/26/2026 02:10:00 PM
- Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board • GlobeNewswire Inc. • 02/23/2026 01:50:00 PM
- Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference • GlobeNewswire Inc. • 02/18/2026 02:05:00 PM
- Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline • GlobeNewswire Inc. • 02/11/2026 01:45:00 PM
- Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial • GlobeNewswire Inc. • 02/05/2026 02:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/03/2026 04:15:12 PM
- Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors • GlobeNewswire Inc. • 01/26/2026 01:45:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/23/2026 10:17:59 PM
